Inventor · disambiguated record
Richard K. Bestwick
Also filed as: BESTWICK RICHARD · BESTWICK RICHARD K · BESTWICK RICHARD KEITH
38 granted patents·34 pending applications·861 citations·filing 1992–2025
98Inventor score
Files withSAREPTA THERAPEUTICS INC45AGRITOPE INC12AVI BIOPHARMA INC3EPITOPE INC3ORASURE TECHNOLOGIES INC2
Top patents by PatentIndex Score
72 records- 0198US7402574B2Antisense composition and method for treating cancerAVI BIOPHARMA INC·Filed 2005·Granted Jul 22, 2008·126 cites·12 claims
- 0297US9217148B2Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2014·Granted Dec 22, 2015·45 cites·6 claims
- 0395US8524676B2Method for treating enterovirus or rhinovirus infection using antisense antiviral compoundsSTEIN DAVID A·Filed 2006·Granted Sep 3, 2013·39 cites·8 claims
- 0494US8759307B2Oligonucleotide compound and method for treating nidovirus infectionsSTEIN DAVID A·Filed 2008·Granted Jun 24, 2014·35 cites·8 claims
- 0593US11384105B2Processes for preparing oligomersSAREPTA THERAPEUTICS INC·Filed 2020·Granted Jul 12, 2022·3 cites·8 claims
- 0692US11071749B2Oligonucleotide analogues targeting human LMNASAREPTA THERAPEUTICS INC·Filed 2019·Granted Jul 27, 2021·3 cites·12 claims
- 0790US10875880B2Processes for preparing oligomersSAREPTA THERAPEUTICS INC·Filed 2017·Granted Dec 29, 2020·5 cites·22 claims
- 0890US5750870APlant genetic transformation methods and transgenic plantsAGRITOPE INC·Filed 1995·Granted May 12, 1998·119 cites·20 claims
- 0990US2025236869A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1090US2025145991A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1189US10758629B2Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2018·Granted Sep 1, 2020·2 cites·4 claims
- 1288US7544468B2Simultaneous collection of DNA and non-nucleic analytesORASURE TECHNOLOGIES INC·Filed 2001·Granted Jun 9, 2009·18 cites·23 claims
- 1387US5859330ARegulated expression of heterologous genes in plants and transgenic fruit with a modified ripening phenotypeAGRITOPE INC·Filed 1994·Granted Jan 12, 1999·116 cites·35 claims
- 1486US10907154B2Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2018·Granted Feb 2, 2021·1 cites·4 claims
- 1585US9066967B2Oligonucleotide analogues targeting human LMNASAREPTA THERAPEUTICS INC·Filed 2012·Granted Jun 30, 2015·4 cites·86 claims
- 1684US10822608B2Oligonucleotide analogues targeting human LMNASAREPTA THERAPEUTICS INC·Filed 2017·Granted Nov 3, 2020·2 cites·4 claims
- 1784US10076536B2Oligonucleotide analogues targeting human LMNASAREPTA THERAPEUTICS INC·Filed 2017·Granted Sep 18, 2018·2 cites·17 claims
- 1881US5783394ARaspberry promoters for expression of transgenes in plantsAGRITOPE INC·Filed 1997·Granted Jul 21, 1998·42 cites·34 claims
- 1981US5783393APlant tissue/stage specific promoters for regulated expression of transgenes in plantsAGRITOPE INC·Filed 1996·Granted Jul 21, 1998·41 cites·13 claims
- 2081US2024042049A1Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2179US6309827B1Simultaneous collection of DNA and non-nucleic analytesORASURE TECHNOLOGIES INC·Filed 1998·Granted Oct 30, 2001·55 cites·22 claims
- 2279US2025171783A1Antisense-induced exon2 inclusion in acid alpha-glucosidaseSAREPTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2379US2022364093A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2479US2023104708A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2578US5965355AAntibodies and proteins useful for assaying virus infection in grape plantsAGRITOPE INC·Filed 1996·Granted Oct 12, 1999·44 cites·14 claims
- 2677US11932851B2Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2020·Granted Mar 19, 2024·0 cites·6 claims
- 2777US2022056442A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2877US2022259592A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2975US11491238B2Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2020·Granted Nov 8, 2022·0 cites·17 claims
- 3075US9682097B2Oligonucleotide analogues targeting human LMNASAREPTA THERAPEUTICS INC·Filed 2015·Granted Jun 20, 2017·1 cites·49 claims
- 3175US5753222AAntibiotic-producing strain of bacillus and methods for controlling plant diseasesAGRITOPE INC·Filed 1996·Granted May 19, 1998·42 cites·9 claims
- 3275US2025179487A1Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3374US2020339985A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3471US2020040336A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3570US2022170024A1Antisense-induced exon2 inclusion in acid alpha-glucosidaseSAREPTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3669US5421121AFloral preservative method and compositionEPITOPE INC·Filed 1994·Granted Jun 6, 1995·17 cites·5 claims
- 3769US2019330624A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3867US11802283B2Oligonucleotide analogues targeting human LMNASAREPTA THERAPEUTICS INC·Filed 2020·Granted Oct 31, 2023·0 cites·4 claims
- 3967US2025290069A1Exon skipping oligomers for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4066US2014315977A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 4166US2016040162A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 4265US11236338B2Antisense-induced exon2 inclusion in acid alpha-glucosidaseSAREPTA THERAPEUTICS INC·Filed 2014·Granted Feb 1, 2022·0 cites·8 claims
- 4365US2022017901A1Exon skipping oligomer conjugates for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4464US2005171044A1Oligonucleotide compound and method for treating nidovirus infectionsFiled 2004·Application pending·0 cites
- 4564US2017369876A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4664US2018016574A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4764US2015126722A1Oligonucleotide compound and method for treating nidovirus infectionsSAREPTA THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 4864US2018002689A1Exon skipping compositions for treating muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4962US2021187003A1Exon skipping oligomers for muscular dystrophySAREPTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 5061US2022090084A1Antisense-induced exon exclusion in myostatinSAREPTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 72 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →